Drug updated on 12/11/2024
| Dosage Form | Vaginal ring (intravaginal; 103 mg segesterone acetate and 17.4 mg ethinyl estradiol) |
| Drug Class | Progestin/estrogen CHCs |
| Ongoing and Completed Studies | ClinicalTrials.gov |
Indication
- Indicated for use by females of reproductive potential to prevent pregnancy.
Latest News
Summary
- This summary is based on the review of one systematic review/meta-analysis. [1]
- High general satisfaction with NuvaRing® was reported by 80-90% of users, with ease of use improving over time across all settings.
- Mixed results were observed for continuation of use, indicating variability in long-term adherence to NuvaRing® among users.
- Sexual satisfaction outcomes were less consistently reported, with mixed results across studies regarding its impact on sexual satisfaction.
- There is no safety information available in the reviewed studies, aside from noting that ring-related events were associated with discontinuation of the contraceptive vaginal ring (CVR).
- The majority of studies on NuvaRing® were conducted in high-income settings, but no specific information is provided regarding population types or subgroups, such as age or comorbid conditions.
Product Monograph / Prescribing Information
| Document Title | Year | Source |
|---|---|---|
| Annovera (segesterone acetate and ethinyl estradiol) Prescribing Information. | 2022 | TherapeuticsMD, Inc., Boca Raton, FL |
Systematic Reviews / Meta-Analyses
| Document Title | Year | Source |
|---|---|---|
| Acceptability and Satisfaction of Contraceptive Vaginal Rings in Clinical Studies: A Systematic Review and Narrative Synthesis. | 2021 | Frontiers in Global Women’s Health |
Clinical Practice Guidelines
| Document Title | Year | Source |
|---|---|---|
| General Approaches to Medical Management of Menstrual Suppression: ACOG Clinical Consensus No. 3 | 2022 | Obstetrics and Gynecology |